Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19

In this study, 20% of patients with Covid-19 had a prolonged activated partial-thromboplastin time. In 90% of these cases, the cause was lupus anticoagulant, with no associated bleeding. Patients with Covid-19 are susceptible to thromboses. The presence of a prolonged aPTT should, in general, not be...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-07, Vol.383 (3), p.288-290
Hauptverfasser:	Bowles, Louise, Platton, Sean, Yartey, Nada, Dave, Minal, Lee, Kurtis, Hart, Daniel P, MacDonald, Vickie, Green, Laura, Sivapalaratnam, Suthesh, Pasi, K. John, MacCallum, Peter
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Aged, 80 and over Anticoagulants Anticoagulants - therapeutic use Betacoronavirus Blood Coagulation Tests Coronavirus Infections - blood Coronaviruses Correspondence COVID-19 Female General & Internal Medicine Humans Life Sciences & Biomedicine Lupus Lupus Coagulation Inhibitor - blood Male Medicine, General & Internal Middle Aged Pandemics Partial Thromboplastin Time Patients Pneumonia, Viral - blood Pulmonary embolisms SARS-CoV-2 Science & Technology Severe acute respiratory syndrome coronavirus 2 Systemic lupus erythematosus Thromboplastin Thrombosis Thrombosis - drug therapy Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In this study, 20% of patients with Covid-19 had a prolonged activated partial-thromboplastin time. In 90% of these cases, the cause was lupus anticoagulant, with no associated bleeding. Patients with Covid-19 are susceptible to thromboses. The presence of a prolonged aPTT should, in general, not be considered a contraindication to anticoagulation.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMc2013656